Method for alleviating cisplatin-induced nephrotoxicity and dithiocarbamate compounds for effecting same

Claim 3

The method of claim 1 wherein said polar dithiocarbamate compound is sodium N-methyl-N-(2-sulfoethyl)-dithiocarbamate.

Claim 4

The method of claim 1 wherein said polar dithiocarbamate compound is sodium N-methyl-N-(2-carboxyethyl)-dithiocarbamate.

Claim 5

The method of claim 1 wherein said polar dithiocarbamate compound is sodium N,N-(2-hydroxyethyl)-dithiocarbamate.

Claim 6

A kit useful for alleviating cisplatin-induced nephrotoxicity comprising a carrier being compartmentalized to receive in close confinement therein more than one container wherein at least a first container contains an effective amount of cisplatin and at least a second container contains an effective amount of a polar dithiocarbamate compound having the general formula: ##STR6## wherein R 1 and R 2 are aliphatic groups selected from the group consisting of branched or straight chain alkyl groups having 1-8 carbon atoms, alicyclic groups selected from the group consisting of cycloparaffins and partially hydrogenated aromatic compounds containing 3-8 carbon atoms, or aromatic groups containing at least 5-6 carbon atoms, or R 1 and R 2 taken together with the nitrogen form a heterocyclic ring containing 5 or 6 members and selected from the group consisting of pyrrole, pyrroline, pyrrolidine, pyridine, and piperidine, and either R 1 , R 2 , or both R 1 and R 2 contain a polar group selected from the group consisting of Cl, Br, I, F, HSO 3 , HCO 3 , NO 2 , NO 3 , SO 3 - , CO 2 - , PO 3 -2 , PO 2 (OH) - , PO 4 -2 , PO 3 (OH) - , OR 3 , N(R 3 ) 2 , and CON(R 3 ) 2 , where R 3 is hydrogen, lower alkyl or alkyl substituted with polar groups, M is a pharmacologically acceptable cation, and n is an integer of 1-3; said polar dithiocarbamate compound forming a platinum (II) complex having a water solubility of at least 0.2 micromoles per ml.

Claim 7

A kit useful for alleviating cisplatin-induced nephrotoxicity comprising a carrier being compartmentalized to receive in close confinement therein more than one container wherein at least a first container contains an effective amount of cisplatin and at least a second container contains an effective amount of a polar dithiocarbamate compound having the general formula: ##STR6## wherein R 1 and R 2 are aliphatic groups selected from the group consisting of branched or straight chain alkyl groups having 1-8 carbon atoms, alicyclic groups selected from the group consisting of cycloparaffins and partially hydrogenated aromatic compounds containing 3-8 carbon atoms, or aromatic groups containing at least 5-6 carbon atoms, or R 1 and R 2 taken together with the nitrogen form a heterocyclic ring containing 5 or 6 members and selected from the group consisting of pyrrole, pyrroline, pyrrolidine, pyridine, and piperidine, and either R 1 , R 2 , or both R 1 and R 2 contain a polar group selected from the group consisting of Cl, Br, I, F, HSO 3 , HCO 3 , NO 2 , NO 3 , SO 3 - , CO 2 - , PO 3 -2 , PO 2 (OH) - , PO 4 -2 , PO 3 (OH) - , OR 3 , N(R 3 ) 2 , and CON(R 3 ) 2 , where R 3 is hydrogen, lower alkyl or alkyl substituted with polar groups, M is a pharmacologically acceptable cation, and n is an integer of 1-3; said polar dithiocarbamate compound forming a platinum (II) complex having a water solubility of at least 0.2 micromoles per ml.

Claim 8

The method of claim 1 wherein said animal is man.

Claim 9

The method of claim 1 wherein said polar dithiocarbamate is administered parenterally.

Claim 10

The method of claim 1 wherein said polar dithiocarbamate is administered at a dosage level in the range of about 0.05 to 500 mg/kg.

Claim 11

The method of claim 1 wherein said polar dithiocarbamate is administered according to a split-dosage regimen.

Claim 12

Sodium N-methyl-N-(2-sulfoethyl)-dithiocarbamate.

Claim 13

Sodium N-methyl-N-(2-sulfoethyl)-dithiocarbamate.